Ribociclib Claims First Ever Overall Survival Benefit for Targeted Therapy Adding the CDK4/6 inhibitor ribociclib to endocrine therapy significantly extended overall survival in younger women with advanced HR+/HER- breast cancer...
Read MoreEpisode Segments: FEATURE: Manslaughter Case of Long Island Doctor [Minute 18:06] In early March, a doctor was accused of writing prescriptions for ‘massive quantities of opioids,’ and was indicted on murder charges...
Read More
Chronic spontaneous urticaria (CSU) symptoms—such as recurrent hives, angioedema, itching, and...
Read More
Psychological Stress and Chronic Urticaria: A Neuro-immuno-cutaneous Crosstalk. A Systematic...
Read More
Chronic spontaneous urticaria is well-described in adults, but less so in children. The aim of...
Read MoreSunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. MET signaling is a key molecular driver in papillary renal cell...
Read MoreEfficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101 In the phase III JAVELIN Renal 101...
Read MoreOutcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Using the IMDC dataset, patients treated with a 1L...
Read MoreTIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib. The TIVO-3 study enrolled subjects with mRCC who failed two or three prior systemic regimens, one of...
Read MoreEnfortumab vedotin (EV) will likely become the new standard of care for treating patients with previously treated locally advanced or metastatic urothelial carcinoma (la/mUC). A recent phase 3 trial showed that treatment with...
Read MoreAlthough the CheckMate-9ER trial, comparing cabozantinib plus nivolumab to sunitinib in frontline metastatic renal cell carcinoma (mRCC), had recently demonstrated superiority in progression-free survival (PFS) and overall...
Read More
Pulmonary disease is a frequent acute and chronic manifestation in sickle cell disease (SCD),...
Read More
Despite referral to a high-risk clinic for poorly controlled asthma, controller medication therapy...
Read More
“The level of asthma control among pediatric patients improved during the COVID-19 lockdown...
Read More
Since approximately 5% to 10% of patients with asthma have severe disease, there is an urgent need...
Read More
Test your knowledge on results on PsA released at ACR Convergence 2020 – take our quiz and...
Read MoreIn the phase 3 multicenter, open-label, randomized CLEAR trial, lenvatinib in combination with pembrolizumab or everolimus demonstrated significant benefits over sunitinib in patients with advanced renal cell carcinoma (RCC)....
Read More1) In an updated analysis of the phase 2 DESTINY-Breast01 study, women with HER2-positive metastatic breast cancer ADC trastuzumab deruxtecan (Enhertu) continued to demonstrate favorable data, including a median progression-free...
Read More
Test your knowledge on SABCS 2020 – take our quiz and see how you compare with your...
Read More